Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
复制标题
DOI：
10.1371/journal.pone.0074345
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Eoli M
中科院分区：
文献类型：
--
作者：
Cuppini L;Calleri A;Bruzzone MG;Prodi E;Anghileri E;Pellegatta S;Mancuso P;Porrati P;Di Stefano AL;Ceroni M;Bertolini F;Finocchiaro G;Eoli M
最近的数据表明，循环内皮细胞和祖细胞（CECs和cep）在接受贝伐单抗治疗的癌症患者中可能具有预测潜力，这种抗体识别血管内皮生长因子（VEGF）。本文报告了68例接受贝伐珠单抗和伊立替康治疗的复发性胶质母细胞瘤（rGBM）患者的CECs和CEPs，以及分别接受贝伐珠单抗单独治疗（n=32，独立数据集A: IDA）和经典抗母细胞化疗（n=14，独立数据集B: IDB）的rGBM患者的两个独立数据集。KPS≥50的rGBM患者接受治疗，直到MRI与RANO标准定义的进展。用六色流式细胞术研究表达肿瘤内皮细胞标志物CD109的CEC以及其他CEC和CEP亚型。CD109+ CEC基线计数高于41.1/ml（第1四分位数）与无进展生存期（PFS， 20周vs 9周，P=0.008）和总生存期（OS， 32周vs 23周，P=0.03）增加相关。更长的PFS（25周vs 8周，P=0.02）和更长的OS（27周vs 17周，P=0.03）在CD109+ CECs高于41.1/ml的IDA中也得到证实，但在IDB中则没有。接受贝伐单抗联合伊立替康或不联合伊立替康治疗的患者在治疗两个月后无MRI进展，CD109+ CECs显著降低：中位PFS为19周；中位生存期29周。基线时出现两个非连续性病变（远处病变）是较短PFS和OS的独立预测因子（P<0.001）。数据鼓励进一步研究CD109+ CECs在贝伐单抗治疗的GBM患者中的预测潜力。
Recent data suggest that circulating endothelial and progenitor cells (CECs and CEPs, respectively) may have predictive potential in cancer patients treated with bevacizumab, the antibody recognizing vascular endothelial growth factor (VEGF). Here we report on CECs and CEPs investigated in 68 patients affected by recurrent glioblastoma (rGBM) treated with bevacizumab and irinotecan and two Independent Datasets of rGBM patients respectively treated with bevacizumab alone (n=32, independent dataset A: IDA) and classical antiblastic chemotherapy (n=14, independent dataset B: IDB). rGBM patients with KPS ≥50 were treated until progression, as defined by MRI with RANO criteria. CECs expressing CD109, a marker of tumor endothelial cells, as well as other CEC and CEP subtypes, were investigated by six-color flow cytometry. A baseline count of CD109+ CEC higher than 41.1/ml (1st quartile) was associated with increased progression free survival (PFS; 20 versus 9 weeks, P=0.008) and overall survival (OS; 32 versus 23 weeks, P=0.03). Longer PFS (25 versus 8 weeks, P=0.02) and OS (27 versus 17 weeks, P=0.03) were also confirmed in IDA with CD109+ CECs higher than 41.1/ml but not in IDB. Patients treated with bevacizumab with or without irinotecan that were free from MRI progression after two months of treatment had significant decrease of CD109+ CECs: median PFS was 19 weeks; median OS 29 weeks. The presence of two non-contiguous lesions (distant disease) at baseline was an independent predictor of shorter PFS and OS (P<0.001). Data encourage further studies on the predictive potential of CD109+ CECs in GBM patients treated with bevacizumab.
登录
查看更多内容
影响因子：
50.5
作者：
Malka, D.;Boige, V.;Farace, F.
通讯作者：
Farace, F.
影响因子：
20.3
作者：
Franco, Marcela;Roswall, Pernilla;Pietras, Kristian
通讯作者：
Pietras, Kristian
影响因子：
--
作者：
Iwamoto FM;Fine HA
通讯作者：
Fine HA
DOI：
10.1073/pnas.1014480108
发表时间：
2011-03-01
影响因子：
11.1
作者：
Keunen, Olivier;Johansson, Mikael;Niclou, Simone P.
通讯作者：
Niclou, Simone P.
影响因子：
2.3
作者：
Gila, Miguel J.;de las Penas, Ramon;Perez-Martin, Xavier
通讯作者：
Perez-Martin, Xavier